Literature DB >> 23483177

Association between bleeding events and in-hospital mortality after percutaneous coronary intervention.

Adnan K Chhatriwalla1, Amit P Amin, Kevin F Kennedy, John A House, David J Cohen, Sunil V Rao, John C Messenger, Steven P Marso.   

Abstract

IMPORTANCE: Bleeding is the most common complication after percutaneous coronary intervention (PCI) and is associated with increased morbidity and health care costs. The incidence of bleeding-related mortality after PCI has not been described in a nationally representative population. Furthermore, the relationships among bleeding risk, bleeding site, and mortality are unclear.
OBJECTIVES: To describe the association between bleeding events and in-hospital mortality after PCI and to estimate the adjusted population attributable risk (estimated as the proportion of mortality risk associated with bleeding events), risk difference, and number needed to harm (NNH) for bleeding-related in-hospital mortality after PCI. DESIGN, SETTING, AND PATIENTS: Data from 3,386,688 procedures in the CathPCI Registry performed in the United States between 2004 and 2011 were analyzed. The population attributable risk was calculated after adjustment for baseline demographic, clinical, and procedural variables. To calculate the NNH for bleeding-related mortality, a propensity-matched analysis was performed. MAIN OUTCOME MEASURES: In-hospital mortality.
RESULTS: There were 57,246 bleeding events (1.7%) and 22,165 in-hospital deaths (0.65%) in 3,386,688 PCI procedures. The adjusted population attributable risk for mortality related to major bleeding was 12.1% (95% CI, 11.4%-12.7%) in the entire CathPCI cohort. The propensity-matched population consisted of 56,078 procedures with a major bleeding event and 224 312 controls. In this matched cohort, major bleeding was associated with increased in-hospital mortality (5.26% vs 1.87%; risk difference, 3.39% [95% CI, 3.20%-3.59%]; NNH = 29 [95% CI, 28-31]; P < .001). The association between major bleeding and in-hospital mortality was observed in all strata of preprocedural bleeding risk (low: 1.62% vs 0.17%; risk difference, 1.45% [95% CI, 1.13%-1.77%], NNH = 69 [95% CI, 57-88], P < .001; intermediate: 3.27% vs 0.71%; risk difference, 2.56% [95% CI, 2.33%-2.79%], NNH = 39 [95% CI, 36-43], P < .001; and high: 8.16% vs 3.45%; risk difference, 4.71% [95% CI, 4.35%-5.07%], NNH = 21 [95% CI, 20-23], P < .001). Although both access-site and non-access-site bleeding were associated with increased in-hospital mortality (2.73% vs 1.87%; risk difference, 0.86% [95% CI, 0.66%-1.05%], NNH = 117 [95% CI, 95-151], P < .001; and 8.25% vs 1.87%; risk difference, 6.39% [95% CI, 6.04%-6.73%], NNH = 16 [95% CI, 15-17], P < .001, respectively), the NNH was lower for nonaccess bleeding. CONCLUSIONS AND RELEVANCE: In a large registry of patients undergoing PCI, postprocedural bleeding events were associated with increased risk of in-hospital mortality, with an estimated 12.1% of deaths related to bleeding complications.

Entities:  

Mesh:

Year:  2013        PMID: 23483177     DOI: 10.1001/jama.2013.1556

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  67 in total

1.  Bleeding Complications in Lower-Extremity Peripheral Vascular Interventions: Insights From the NCDR PVI Registry.

Authors:  Bhaskar Bhardwaj; John A Spertus; Kevin F Kennedy; W Schuyler Jones; David Safley; Thomas T Tsai; Herbert D Aronow; Amit N Vora; Yashashwi Pokharel; Arun Kumar; Robert R Attaran; Dmitriy N Feldman; Ehrin Armstrong; Anand Prasad; Bruce Gray; Adam C Salisbury
Journal:  JACC Cardiovasc Interv       Date:  2019-06-24       Impact factor: 11.195

Review 2.  Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials.

Authors:  Thomas G Nührenberg; Willibald Hochholzer; Kambis Mashayekhi; Miroslaw Ferenc; Franz-Josef Neumann
Journal:  Clin Res Cardiol       Date:  2018-04-13       Impact factor: 5.460

3.  Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable?

Authors:  Neil J Wimmer; David J Cohen; Jason H Wasfy; Saif S Rathore; Laura Mauri; Robert W Yeh
Journal:  Am Heart J       Date:  2014-04-04       Impact factor: 4.749

4.  Clopidogrel Therapy in Patients with Cardiovascular Disease Undergoing Transurethral Resection of the Prostate: A Step Towards Individualization.

Authors:  Petros Tzimas; Maria Tsoumani; Dimitrios Giannakis; Kallirroi Kalantzi; Anastasios Petrou; Vasileios Chantzichristos; Nikolaos Sofikitis; Georgios Papadopoulos; Haralampos Milionis; Alexandros Tselepis
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

5.  Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention.

Authors:  Gjin Ndrepepa; Elena Guerra; Stefanie Schulz; Massimiliano Fusaro; Salvatore Cassese; Adnan Kastrati
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

Review 6.  Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.

Authors:  Partha Sardar; Ramez Nairooz; Saurav Chatterjee; Savi Mushiyev; Gerald Pekler; Ferdinand Visco
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

7.  Major Bleeding and Adverse Outcome following Percutaneous Coronary Intervention.

Authors:  Eric W Holroyd; Ahmad Hs Mustafa; Chee W Khoo; Rob Butler; Douglas G Fraser; Jim Nolan; Mamas A Mamas
Journal:  Interv Cardiol       Date:  2015-03

Review 8.  Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation.

Authors:  Mahesh V Madhavan; Ajay J Kirtane
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

Review 9.  Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare.

Authors:  Sean Esmonde; Divyesh Sharma; Aaron Peace
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

10.  Experimental Validation of ARFI Surveillance of Subcutaneous Hemorrhage (ASSH) Using Calibrated Infusions in a Tissue-Mimicking Model and Dogs.

Authors:  Rebecca E Geist; Chase H DuBois; Timothy C Nichols; Melissa C Caughey; Elizabeth P Merricks; Robin Raymer; Caterina M Gallippi
Journal:  Ultrason Imaging       Date:  2015-11-27       Impact factor: 1.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.